Financial OutlookThe 12-month price target for Instil Bio has been increased to $125 from the previous $105, indicating a stronger financial outlook.
Potential Acquisition InterestThe rising values of these transactions should provide further confidence that the highly positive clinical impact of these PD-1/L1 x VEGF bispecifics is real and highlights potential for Instil Bio to become an acquisition target of interest, given encouraging data generated to date.
Stock PerformanceUpon the unveiling of the full HARMONi-2 dataset, read-through to Instil Bio led to a nearly 500% increase in the TIL stock price.